4D pharma plc (AIM: DDDD), a clinical stage biopharmaceutical company, pioneering the development of Live Biotherapeutic Products, today announced an agreement with a subsidiary of MSD (tradename of Merck & Co., Inc., Kenilworth, N.J., USA) […]
An analysis comparing the intestinal microbiomes of both infants and adults living in rural and urban areas of Nigeria has revealed that not only are there many differences in adults living in subsistence environments versus […]
Microbiotica, a leading player in microbiome-based therapeutics spun out of the Wellcome Sanger Institute, today announced that it has entered into a multi-year strategic collaboration with Genentech, a member of the Roche Group, to discover, […]
4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of live biotherapeutics, today announced that the Company has submitted, and the Medicines and Healthcare products Regulatory Agency (MHRA) has cleared, a Clinical Trial […]
Thryve, providers of high quality microbiotics and microbiome testing, announced today it has secured $1.4 million in funding. Participating investment firms include PivotNorth Capital, Unilever Ventures, Darling Ventures, Candela Paramount, Abstract Ventures and Joyance Partners. […]
Lodo Therapeutics Corporation, a drug discovery and development company focused on identifying and producing unique, bioactive natural products directly from the microbial DNA sequence information contained in soil, today announced that it has formed a […]
4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of live biotherapeutics, has today announced that the Company has submitted, and the U.S. Food and Drug Administration (FDA) has cleared, an Investigational New […]
A-Mansia Biotech S.A. (A-Mansia), the microbiome company focused on developing products based on the unique properties of the Akkermansia muciniphila (A. muciniphila) bacterium, today announces a €13 million first close of its Series A financing, […]
Inocucor Corporation, a developer and producer of biological crop inputs for high-value produce and row crops, announced the final close of its Series B funding round at $15.9 million with participation by existing investors Cycle […]
Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage company applying synthetic biology to probiotics to develop novel living medicines, today announced that it has agreed to sell 3,280,000 shares of its common stock to a large mutual […]
Osaka, Japan and Somerville, MA, April 5 2017 – Finch Therapeutics, a privately held microbiome engineering company, and Takeda Pharmaceutical Company Limited (“Takeda”) (TSE: 4502), today announced a global collaboration agreement to jointly develop FIN-524. […]